Menu
Recruiting NCT07572760

Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

No phase Interventional Prostatic Neoplasms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Power training group.
Who it may be relevant to
Registry conditions: Prostatic Neoplasms. Basic parameters: from 50 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.

Overview

The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are: * Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy? * Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy? Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer. Participants will: * Participate in a supervised exercise program twice a week for 6 months or maintain routine care. * Perform fitness tests and questionnaires about quality of life and mental health. * Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.

Detailed description

Background and Rationale:

Prostate cancer is the most frequently diagnosed cancer among men worldwide, particularly affecting older populations, with increasing incidence and prevalence projected in the coming decades. While survival rates have improved substantially, these advances have not been matched by improvements in long-term quality of life. A significant proportion of patients with advanced prostate cancer undergo androgen deprivation therapy (ADT), which reduces testosterone levels to control tumor progression.

Despite its effectiveness, ADT is associated with multiple adverse effects, including loss of muscle mass and strength, increased adiposity, decreased bone mineral density, chronic fatigue, and metabolic alterations. These changes resemble an accelerated aging process and increase the risk of sarcopenia, osteoporosis, and functional dependency. In addition, ADT has been linked to psychological disturbances, including depression, anxiety, cognitive impairment, and reduced vitality.

Health-related quality of life (HRQoL) is a multidimensional construct encompassing physical, psychological, and social domains. In prostate cancer patients undergoing ADT, quality of life is significantly impaired due to the combined effects of disease burden and treatment-related side effects. Mental health plays a central role in this construct, as cancer diagnosis and treatment are highly stressful experiences that can disrupt identity, autonomy, and life continuity.

Exercise has been identified as an effective non-pharmacological intervention for mitigating many of the adverse effects of ADT. Systematic reviews and meta-analyses have demonstrated that exercise improves muscle strength, cardiorespiratory fitness, functional performance, fatigue, and body composition in this population. Exercise has also been associated with improvements in quality of life and emotional well-being, particularly when interventions are supervised and long-term.

The mechanisms underlying these benefits are multifactorial. Neurobiological processes include increased levels of neurotransmitters and brain-derived neurotrophic factor (BDNF), as well as reduced systemic inflammation. From a psychosocial perspective, exercise enhances self-efficacy, perceived control, and social interaction, all of which contribute to improved mental health.

However, most existing research has focused on aerobic or traditional resistance training protocols aimed at hypertrophy. There is a lack of studies examining power-oriented resistance training, which emphasizes rapid force production at moderate loads. Muscle power declines more rapidly than strength with aging and is a critical determinant of functional independence. It is particularly relevant for activities of daily living such as standing up, climbing stairs, or maintaining balance.

Given that ADT induces an accelerated decline in neuromuscular function, power-oriented training may be especially beneficial in this population. Furthermore, this type of training may use lower loads and avoid excessive fatigue, which may enhance adherence in patients experiencing chronic fatigue.

Additionally, previous studies have relied predominantly on quantitative measures, which may not fully capture the subjective and psychosocial dimensions of exercise participation. A mixed-methods approach is therefore necessary to understand how exercise influences identity, motivation, and psychological adaptation in men with prostate cancer.

Objectives:

Primary Objective

1. To determine the effects of a power-oriented resistance training program on health-related quality of life in older men with metastatic prostate cancer undergoing androgen deprivation therapy. 2. To assess improvements in functional capacity, including strength, balance, and performance in daily activities.

Secondary Objectives

1. To evaluate the effects on mental health outcomes, including anxiety, depression, emotional well-being and self-esteem. 2. To determine the safety and feasibility of power-oriented resistance training. 3. To explore participants' subjective experiences using qualitative methods.

Hypotheses:

1. The intervention will significantly improve quality of life compared to the control group. 2. Power-oriented resistance training will be safe and well tolerated. 3. Functional capacity will significantly improve following the intervention. 4. Participants will show improved mental health outcomes. 5. Qualitative findings will reveal improvements in self-efficacy, identity, and psychosocial adaptation.

Study Design:

This study is a randomized controlled trial (RCT) with a mixed-methods approach.

Participants will be randomly assigned to: * Experimental Group: Power-Oriented Resistance Training * Control Group: Usual care, with information and guidance on how to be physically active at home.

The intervention will last 24 weeks, with a 6-month follow-up.

Participants:

A total of 66 participants will be recruited, based on power analysis (α = 0.05; power = 0.80; effect size = 0.5). An attrition rate of 20% was also considered.

Inclusion Criteria: * Histopathologically confirmed diagnosis of prostate adenocarcinoma.

• Metastatic hormone-sensitive prostate cancer (mHSPC), defined as: * Presence of metastases at initial diagnosis (synchronous mHSPC), or * Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC). • Evidence of progression to castration-resistant prostate cancer (CRPC).

* Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment. * Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates. * Presence of metastatic involvement limited to bone and/or lymph nodes. * Functionally independent in activities of daily living.

Exclusion Criteria: * Evidence of visceral metastatic disease. * Current or prior treatment with a triplet regimen that includes chemotherapy. * History of pathological fracture.

Intervention:

Power-Oriented Resistance Training

• Frequency: 2 sessions/week. * Intensity: 40-50% 1RM. * Execution: High-velocity concentric phase. * Volume: Low to moderate. * No training to failure. This model is designed to improve functional performance while minimizing fatigue and injury risk.

Control Group:

Participants will receive information and guidance for being physically active and perform strength training at home.

Outcome Measures:

Primary Outcome • Health-related quality of life (FACT-P).

Secondary Outcomes

• Functional capacity: (Rate of force development; Handgrip test; Timed up and go test; 6-Minute Walk Test; 10-meter walking speed; 5 times Sit to stand test).

• Mental health (anxiety, depression and stress): DASS-21.

• Self-esteem: Rosenberg scale.

• Physical activity levels: (IPAQ SF).

• Adverse events (field diary).

Qualitative Analysis

Interventions

  • Other Power training group
    The intervention consists of a supervised power-oriented resistance training program for older men with prostate cancer undergoing androgen deprivation therapy (ADT). Participants will complete 2 sessions per week over 24 weeks. Training focuses on improving muscle power through exercises performed at moderate intensity (40-50% 1RM), emphasizing a fast concentric phase and controlled eccentric phase. Multi-joint functional exercises targeting major muscle groups are included to enhance strength,

Primary outcome measures

  • Health-related quality of life [Time frame: From enrollment to the end of the exercise program at 6 months.]
Secondary outcome measures (11)
  • Rate of Force Development [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Lower-body strength [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Handgrip strength [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Functional mobility [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Gait speed [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Functional aerobic capacity [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Static balance [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Mental health [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Self-esteem [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Physical activity level [Time frame: From enrollment to the end of the exercise program at 6 months.]
  • Body composition [Time frame: From enrollment to the end of the exercise program at 6 months.]

Eligibility criteria

Inclusion criteria

  • Histopathologically confirmed diagnosis of prostate adenocarcinoma.
  • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as:
  • Presence of metastases at initial diagnosis (synchronous mHSPC), or
  • Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC).
  • Evidence of progression to castration-resistant prostate cancer (CRPC).
  • Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment.
  • Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates.
  • Presence of metastatic involvement limited to bone and/or lymph nodes.
  • Functionally independent in activities of daily living.

Exclusion criteria

  • Evidence of visceral metastatic disease.
  • Current or prior treatment with a triplet regimen that includes chemotherapy.
  • History of pathological fracture.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Spain · 1 center
  • University of Alicante — San Vicent del Raspeig

Publications

  • Aagaard P, Simonsen EB, Andersen JL, Magnusson P, Dyhre-Poulsen P. Neural adaptation to resistance training: changes in evoked V-wave and H-reflex responses. J Appl Physiol (1985). 2002 Jun;92(6):2309-18. doi: 10.1152/japplphysiol.01185.2001. PMID 12015341
  • Bassyouny NM, Gouda MM, Ezz El Din MM, Sweed HS, El Akkad RM. Impact of Androgen Deprivation Therapy on Cognitive Function of Elderly Men With Prostate Cancer. Cureus. 2024 Sep 12;16(9):e69303. doi: 10.7759/cureus.69303. eCollection 2024 Sep. PMID 39398693
  • Bigaran A, Zopf E, Gardner J, La Gerche A, Murphy DG, Howden EJ, Baker MK, Cormie P. The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):35-48. doi: 10.1038/s41391-020-00273-5. Epub 2020 Aug 28. PMID 32860010
  • Cormie P, Turner B, Kaczmarek E, Drake D, Chambers SK. A qualitative exploration of the experience of men with prostate cancer involved in supervised exercise programs. Oncol Nurs Forum. 2015 Jan;42(1):24-32. doi: 10.1188/15.ONF.24-32. PMID 25542318
  • El Hadouchi M, Kiers H, Veenhof C, Van Dieen J. The Impact of Power Training on Muscle Power, Physical Performance, and Physical Functioning in Older Adults: A Descriptive Case Series. Clin Interv Aging. 2025 Jun 16;20:849-857. doi: 10.2147/CIA.S511954. eCollection 2025. PMID 40547363
  • Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. PMID 24344218
  • Lopez P, Taaffe DR, Newton RU, Buffart LM, Galvao DA. What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):465-481. doi: 10.1038/s41391-020-00301-4. Epub 2020 Nov 20. PMID 33219369
  • Maffiuletti NA, Aagaard P, Blazevich AJ, Folland J, Tillin N, Duchateau J. Rate of force development: physiological and methodological considerations. Eur J Appl Physiol. 2016 Jun;116(6):1091-116. doi: 10.1007/s00421-016-3346-6. Epub 2016 Mar 3. PMID 26941023

Identifiers

NCT: NCT07572760 · UA-2024-01- 23_2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗